Logo image of ADN

ADVENT TECHNOLOGIES HOLDINGS (ADN) Stock Fundamental Analysis

USA - NASDAQ:ADN - US00788A2042 - Common Stock

0.9185 USD
-1.79 (-66.11%)
Last: 10/29/2025, 8:12:04 PM
0.88 USD
-0.04 (-4.19%)
After Hours: 10/29/2025, 8:12:04 PM
Fundamental Rating

2

ADN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 91 industry peers in the Electrical Equipment industry. Both the profitability and financial health of ADN have multiple concerns. ADN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ADN had negative earnings in the past year.
In the past year ADN has reported a negative cash flow from operations.
In the past 5 years ADN always reported negative net income.
ADN had a negative operating cash flow in each of the past 5 years.
ADN Yearly Net Income VS EBIT VS OCF VS FCFADN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -612.77%, ADN is not doing good in the industry: 95.65% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -612.77%
ROE N/A
ROIC N/A
ROA(3y)-266.83%
ROA(5y)-195.57%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ADN Yearly ROA, ROE, ROICADN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

ADN has a Gross Margin of 54.58%. This is amongst the best in the industry. ADN outperforms 97.83% of its industry peers.
In the last couple of years the Gross Margin of ADN has grown nicely.
ADN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.39%
GM growth 5Y8.72%
ADN Yearly Profit, Operating, Gross MarginsADN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

0

2. Health

2.1 Basic Checks

ADN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADN has been increased compared to 1 year ago.
ADN has more shares outstanding than it did 5 years ago.
ADN has a worse debt/assets ratio than last year.
ADN Yearly Shares OutstandingADN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M
ADN Yearly Total Debt VS Total AssetsADN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ADN has an Altman-Z score of -61.07. This is a bad value and indicates that ADN is not financially healthy and even has some risk of bankruptcy.
ADN has a Altman-Z score of -61.07. This is amonst the worse of the industry: ADN underperforms 93.48% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -61.07
ROIC/WACCN/A
WACC10.76%
ADN Yearly LT Debt VS Equity VS FCFADN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

ADN has a Current Ratio of 0.05. This is a bad value and indicates that ADN is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.05, ADN is not doing good in the industry: 94.57% of the companies in the same industry are doing better.
ADN has a Quick Ratio of 0.05. This is a bad value and indicates that ADN is not financially healthy enough and could expect problems in meeting its short term obligations.
ADN's Quick ratio of 0.05 is on the low side compared to the rest of the industry. ADN is outperformed by 94.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.05
Quick Ratio 0.05
ADN Yearly Current Assets VS Current LiabilitesADN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.98% over the past year.
ADN shows a strong growth in Revenue. In the last year, the Revenue has grown by 113.28%.
The Revenue has been growing by 39.50% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)57.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.71%
Revenue 1Y (TTM)113.28%
Revenue growth 3Y-22.61%
Revenue growth 5Y39.5%
Sales Q2Q%-87.7%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year91.56%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ADN Yearly Revenue VS EstimatesADN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
ADN Yearly EPS VS EstimatesADN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADN. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 9.09, the valuation of ADN can be described as very reasonable.
Based on the Price/Forward Earnings ratio, ADN is valued cheaper than 96.74% of the companies in the same industry.
ADN's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 35.42.
Industry RankSector Rank
PE N/A
Fwd PE 9.09
ADN Price Earnings VS Forward Price EarningsADN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADN Per share dataADN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15

4.3 Compensation for Growth

ADN's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

ADN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ADVENT TECHNOLOGIES HOLDINGS

NASDAQ:ADN (10/29/2025, 8:12:04 PM)

After market: 0.88 -0.04 (-4.19%)

0.9185

-1.79 (-66.11%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryElectrical Equipment
Earnings (Last)10-20 2025-10-20
Earnings (Next)12-26 2025-12-26
Inst Owners8%
Inst Owner Change74%
Ins Owners10.33%
Ins Owner Change0%
Market Cap3.02M
Revenue(TTM)3.28M
Net Income(TTM)-40.99M
Analysts45
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 9.09
P/S 0.92
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-15.65
EYN/A
EPS(NY)0.1
Fwd EY11%
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS1
BVpS-8.94
TBVpS-8.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -612.77%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.58%
FCFM N/A
ROA(3y)-266.83%
ROA(5y)-195.57%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y32.39%
GM growth 5Y8.72%
F-Score4
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.55%
Cap/Sales 2.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.05
Quick Ratio 0.05
Altman-Z -61.07
F-Score4
WACC10.76%
ROIC/WACCN/A
Cap/Depr(3y)123.72%
Cap/Depr(5y)228.29%
Cap/Sales(3y)123.53%
Cap/Sales(5y)88.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.71%
EPS Next Y600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)113.28%
Revenue growth 3Y-22.61%
Revenue growth 5Y39.5%
Sales Q2Q%-87.7%
Revenue Next Year91.56%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year760%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y90.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.33%
OCF growth 3YN/A
OCF growth 5YN/A

ADVENT TECHNOLOGIES HOLDINGS / ADN FAQ

What is the ChartMill fundamental rating of ADVENT TECHNOLOGIES HOLDINGS (ADN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to ADN.


What is the valuation status for ADN stock?

ChartMill assigns a valuation rating of 3 / 10 to ADVENT TECHNOLOGIES HOLDINGS (ADN). This can be considered as Overvalued.


How profitable is ADVENT TECHNOLOGIES HOLDINGS (ADN) stock?

ADVENT TECHNOLOGIES HOLDINGS (ADN) has a profitability rating of 1 / 10.


How financially healthy is ADVENT TECHNOLOGIES HOLDINGS?

The financial health rating of ADVENT TECHNOLOGIES HOLDINGS (ADN) is 0 / 10.